BCAB
Price
$0.82
Change
+$0.04 (+5.13%)
Updated
Dec 12 closing price
Capitalization
48.47M
96 days until earnings call
Intraday BUY SELL Signals
CELC
Price
$105.25
Change
+$4.48 (+4.45%)
Updated
Dec 12 closing price
Capitalization
4.87B
96 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCAB vs CELC

Header iconBCAB vs CELC Comparison
Open Charts BCAB vs CELCBanner chart's image
BioAtla
Price$0.82
Change+$0.04 (+5.13%)
Volume$979.37K
Capitalization48.47M
Celcuity
Price$105.25
Change+$4.48 (+4.45%)
Volume$1.28M
Capitalization4.87B
BCAB vs CELC Comparison Chart in %
BCAB
Daily Signal:
Gain/Loss:
CELC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCAB vs. CELC commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAB is a Hold and CELC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (BCAB: $0.78 vs. CELC: $100.77)
Brand notoriety: BCAB and CELC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAB: 38% vs. CELC: 77%
Market capitalization -- BCAB: $48.47M vs. CELC: $4.87B
BCAB [@Biotechnology] is valued at $48.47M. CELC’s [@Biotechnology] market capitalization is $4.87B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAB’s FA Score shows that 0 FA rating(s) are green whileCELC’s FA Score has 1 green FA rating(s).

  • BCAB’s FA Score: 0 green, 5 red.
  • CELC’s FA Score: 1 green, 4 red.
According to our system of comparison, CELC is a better buy in the long-term than BCAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAB’s TA Score shows that 4 TA indicator(s) are bullish while CELC’s TA Score has 3 bullish TA indicator(s).

  • BCAB’s TA Score: 4 bullish, 6 bearish.
  • CELC’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both BCAB and CELC are a bad buy in the short-term.

Price Growth

BCAB (@Biotechnology) experienced а -7.64% price change this week, while CELC (@Biotechnology) price change was -4.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

BCAB is expected to report earnings on Mar 19, 2026.

CELC is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($4.87B) has a higher market cap than BCAB($48.5M). CELC YTD gains are higher at: 669.824 vs. BCAB (32.476). BCAB has higher annual earnings (EBITDA): -65.71M vs. CELC (-148.31M). CELC has more cash in the bank: 455M vs. BCAB (8.32M). BCAB has less debt than CELC: BCAB (6.18M) vs CELC (320M). BCAB (0) and CELC (0) have equivalent revenues.
BCABCELCBCAB / CELC
Capitalization48.5M4.87B1%
EBITDA-65.71M-148.31M44%
Gain YTD32.476669.8245%
P/E RatioN/AN/A-
Revenue00-
Total Cash8.32M455M2%
Total Debt6.18M320M2%
FUNDAMENTALS RATINGS
CELC: Fundamental Ratings
CELC
OUTLOOK RATING
1..100
66
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
7
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCABCELC
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
82%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BCAB
Daily Signal:
Gain/Loss:
CELC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VISVX52.290.55
+1.06%
Vanguard Small Cap Value Index Inv
WCMGX34.080.23
+0.68%
First Trust WCM Focused Global Gr Inst
SAGYX154.48N/A
N/A
ClearBridge Growth I
TPYYX8.83-0.02
-0.23%
Touchstone Sands Capital Intl Gr Eq Y
UEMPX10.42-0.03
-0.29%
UBS Emerging Markets Equity Opp P

BCAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAB has been loosely correlated with AXON. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAB
1D Price
Change %
BCAB100%
+1.23%
AXON - BCAB
41%
Loosely correlated
+2.22%
VCYT - BCAB
38%
Loosely correlated
-2.56%
CTMX - BCAB
38%
Loosely correlated
+4.10%
GALT - BCAB
35%
Loosely correlated
+4.01%
CELC - BCAB
33%
Loosely correlated
-1.04%
More

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-1.04%
IMA - CELC
80%
Closely correlated
+0.62%
NEVPF - CELC
61%
Loosely correlated
N/A
MRSN - CELC
58%
Loosely correlated
+0.43%
SLXN - CELC
53%
Loosely correlated
+0.66%
ABOS - CELC
44%
Loosely correlated
+3.16%
More